<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Okamura SM</submitter><funding>Japan Society for the Promotion of Science</funding><pagination>1815</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12648907</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Photodynamic therapy (PDT) utilizing 5-aminolevulinic acid (5-ALA) as a photosensitizing precursor is an approved treatment modality for several types of cancers. However, the increased generation of antioxidants in cancer cells renders them resistant to PDT. MYCN-amplified neuroblastoma shows increased production of reactive oxygen species (ROS) and relies on the glutathione redox system for ROS detoxification. We tested the effectiveness of combining 6-aminonicotinamide (6-AN), a glucose-6-phosphate dehydrogenase inhibitor that modulates nicotinamide adenine dinucleotide phosphate and glutathione redox balance, with PDT for treating neuroblastoma.&lt;h4>Methods&lt;/h4>Cellular protoporphyrin IX (PpIX) accumulation, cell proliferation, morphological changes, induction of cell</pubmed_abstract><journal>BMC cancer</journal><pubmed_title>6-Aminonicotinamide enhances the efficacy of 5-aminolevulinic acid-mediated photodynamic therapy for neuroblastoma.</pubmed_title><pmcid>PMC12648907</pmcid><funding_grant_id>21K07191 and 25K11091</funding_grant_id><pubmed_authors>Chelakkot VS</pubmed_authors><pubmed_authors>Nakahata K</pubmed_authors><pubmed_authors>Hori H</pubmed_authors><pubmed_authors>Okamura SM</pubmed_authors><pubmed_authors>Linn Z</pubmed_authors><pubmed_authors>Toyoda H</pubmed_authors><pubmed_authors>Onishi Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>6-Aminonicotinamide enhances the efficacy of 5-aminolevulinic acid-mediated photodynamic therapy for neuroblastoma.</name><description>&lt;h4>Background&lt;/h4>Photodynamic therapy (PDT) utilizing 5-aminolevulinic acid (5-ALA) as a photosensitizing precursor is an approved treatment modality for several types of cancers. However, the increased generation of antioxidants in cancer cells renders them resistant to PDT. MYCN-amplified neuroblastoma shows increased production of reactive oxygen species (ROS) and relies on the glutathione redox system for ROS detoxification. We tested the effectiveness of combining 6-aminonicotinamide (6-AN), a glucose-6-phosphate dehydrogenase inhibitor that modulates nicotinamide adenine dinucleotide phosphate and glutathione redox balance, with PDT for treating neuroblastoma.&lt;h4>Methods&lt;/h4>Cellular protoporphyrin IX (PpIX) accumulation, cell proliferation, morphological changes, induction of cell</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T17:54:56.259Z</modification><creation>2026-05-19T03:12:02.826Z</creation></dates><accession>S-EPMC12648907</accession><cross_references><pubmed>41291487</pubmed><doi>10.1186/s12885-025-15231-4</doi></cross_references></HashMap>